The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors

Table 1

List of studies on the combination of SBRT and immunotherapy in many cancers.

Author	Disease	N	RT	ICI	Schedule	Abscopal Effects
Twyman Nature [33]	Melanoma	22	6Gy x 2-3; 8Gy x 2-3; (One Site)	Ipilimumab 3mg/kg/3w x4	Ipilimumab 3-5 days after RT	PD: 64% SD: 18%; PR: 18%; CR: None
Hiniker IJROBP 2016 [34]	Melanoma	22	8Gy x 3; 4Gy x 10; (1-2 Sites)	Ipilimumab 3mg/kg/3w x4	RT within 5 days of Ipilimumab	SD: 23%; PR: 14%; CR: 14%
Tang CI. Can Res 2017 [35]	NSCLC, colorectal cancer (CRC), RCC, Others	35	12Gy x 4; 6Gy x 10; (1 Site)	Ipilimumab 3mg/kg/3w x4	RT 1 day after Ipilimumab or 1 week after Ipilimumab	PR: 10%; SD: 23%; CR: None
Luke JCO 2018 [36]	Ovarian, Endometrial, CRC, Others	73	30-50Gy (3-5, 2-4 Sites)	Pembrolizumab 200mg/3 weeks until progression, death, or toxicity	Pembrolizumab 7 days after SBRT	PD: 38; SD: 21; PR: 8; CR: 1